Physicians Prioritize Efficacy, Access in Weight Loss Drug Surge

A new study indicates that physicians prioritize efficacy, safety, and insurance coverage when prescribing GLP-1 weight loss medications, with 94% ranking the benefit-safety profile as crucial. The current options, such as Novo Nordisk's Wegovy and Eli Lilly's Zepbound, have gastrointestinal side effects that doctors wish to see improved upon. While pharmaceutical investments are increasing to develop better GLP-1 options, there is concern that resources may be misallocated toward less critical areas. Access to these medications remains a challenge, as many employers and insurers are scaling back coverage, and Medicare does not cover them for obesity treatment, leaving patients vulnerable to high out-of-pocket costs. A significant portion of the American public supports expanding insurance coverage for obesity medications, emphasizing their importance in addressing the obesity epidemic. The growing demand for effective treatments highlights the need for better coverage and accessibility in the healthcare system.